EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu

Dow Jones

2024-10-29

By Sabela Ojea

Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema.

The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year.

The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial.

Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health.

The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

October 28, 2024 12:00 ET (16:00 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2479436396"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479436396\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2479436396?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479436396","market":"sg","top_or_hot":-1,"title":"EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n</p>\n<p>\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n</p>\n<p>\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n</p>\n<p>\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n</p>\n<p>\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 12:00 ET (16:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-10-29 00:00</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n</p>\n<p>\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n</p>\n<p>\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n</p>\n<p>\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n</p>\n<p>\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 12:00 ET (16:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYPT","symbol_name":"EyePoint","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479436396","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479436396","pubTimestamp":1730131200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema.The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year.The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial.Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health.The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EYPT":"EyePoint"},"translate_title":"Duravyu临床试验数据积极，EyePoint Pharmaceuticals股价上涨35%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n\n\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n\n\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n\n\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n\n\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 12:00 ET (16:00 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}